Tackling CMV in Transplant Recipients: Past, Present, and Future
Abstract Cytomegalovirus (CMV), a beta-herpesvirus capable of maintaining lifelong latency, presents a substantial risk to transplant recipients, resulting in significant morbidity and mortality among both hematopoietic stem cell and solid organ transplantation recipients. Recent advances have shift...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-04-01
|
| Series: | Infectious Diseases and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40121-025-01159-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850218425208537088 |
|---|---|
| author | Tal Schlaeffer-Yosef Lior Nesher |
| author_facet | Tal Schlaeffer-Yosef Lior Nesher |
| author_sort | Tal Schlaeffer-Yosef |
| collection | DOAJ |
| description | Abstract Cytomegalovirus (CMV), a beta-herpesvirus capable of maintaining lifelong latency, presents a substantial risk to transplant recipients, resulting in significant morbidity and mortality among both hematopoietic stem cell and solid organ transplantation recipients. Recent advances have shifted management from reactive approaches, such as preemptive therapy, to preventive strategies to reduce active infections and disease burden. Letermovir, a selective CMV terminase inhibitor, has emerged as a critical prophylactic agent in high-risk transplant populations, significantly lowering infection rates and improving survival with fewer adverse effects than older antivirals. Maribavir, a UL97 kinase inhibitor, is another recently approved promising option for treating CMV, especially in patients with ganciclovir-resistant or refractory CMV infections. Despite these achievements, the risk of late-onset CMV infection after prophylaxis discontinuation remains a significant clinical challenge. Current research seeks to refine prophylactic regimens and develop advanced diagnostic tools, notably interferon-gamma release assays that measure CMV-specific T cell responses. These immunologic assays may help clinicians identify individuals capable of controlling CMV replication, thus guiding the safer discontinuation of prophylaxis and reducing unnecessary drug exposure. Conversely, patients lacking robust immune reconstitution could be targeted for extended prophylaxis or closer follow-up. Looking into the future, ongoing innovations in immune monitoring and antiviral development will likely lead to a more personalized approach to CMV prevention and treatment, optimizing care based on patient-specific risk profiles and immune competence. As this field continues to evolve, integrating novel therapies, improved diagnostics, and immunity-driven protocols holds promise for further reducing CMV-related complications and improving overall outcomes for transplant recipients. |
| format | Article |
| id | doaj-art-0bfa35a5964d4be8a05a1655411faca1 |
| institution | OA Journals |
| issn | 2193-8229 2193-6382 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Infectious Diseases and Therapy |
| spelling | doaj-art-0bfa35a5964d4be8a05a1655411faca12025-08-20T02:07:45ZengAdis, Springer HealthcareInfectious Diseases and Therapy2193-82292193-63822025-04-011461183120010.1007/s40121-025-01159-6Tackling CMV in Transplant Recipients: Past, Present, and FutureTal Schlaeffer-Yosef0Lior Nesher1Infectious Diseases Institute, Soroka University Medical Center, and the Faculty of Health Sciences, Ben-Gurion University of the NegevInfectious Diseases Institute, Soroka University Medical Center, and the Faculty of Health Sciences, Ben-Gurion University of the NegevAbstract Cytomegalovirus (CMV), a beta-herpesvirus capable of maintaining lifelong latency, presents a substantial risk to transplant recipients, resulting in significant morbidity and mortality among both hematopoietic stem cell and solid organ transplantation recipients. Recent advances have shifted management from reactive approaches, such as preemptive therapy, to preventive strategies to reduce active infections and disease burden. Letermovir, a selective CMV terminase inhibitor, has emerged as a critical prophylactic agent in high-risk transplant populations, significantly lowering infection rates and improving survival with fewer adverse effects than older antivirals. Maribavir, a UL97 kinase inhibitor, is another recently approved promising option for treating CMV, especially in patients with ganciclovir-resistant or refractory CMV infections. Despite these achievements, the risk of late-onset CMV infection after prophylaxis discontinuation remains a significant clinical challenge. Current research seeks to refine prophylactic regimens and develop advanced diagnostic tools, notably interferon-gamma release assays that measure CMV-specific T cell responses. These immunologic assays may help clinicians identify individuals capable of controlling CMV replication, thus guiding the safer discontinuation of prophylaxis and reducing unnecessary drug exposure. Conversely, patients lacking robust immune reconstitution could be targeted for extended prophylaxis or closer follow-up. Looking into the future, ongoing innovations in immune monitoring and antiviral development will likely lead to a more personalized approach to CMV prevention and treatment, optimizing care based on patient-specific risk profiles and immune competence. As this field continues to evolve, integrating novel therapies, improved diagnostics, and immunity-driven protocols holds promise for further reducing CMV-related complications and improving overall outcomes for transplant recipients.https://doi.org/10.1007/s40121-025-01159-6CytomegalovirusInterferon-gamma release assayLetermovirMaribavirGanciclovirBone marrow transplant |
| spellingShingle | Tal Schlaeffer-Yosef Lior Nesher Tackling CMV in Transplant Recipients: Past, Present, and Future Infectious Diseases and Therapy Cytomegalovirus Interferon-gamma release assay Letermovir Maribavir Ganciclovir Bone marrow transplant |
| title | Tackling CMV in Transplant Recipients: Past, Present, and Future |
| title_full | Tackling CMV in Transplant Recipients: Past, Present, and Future |
| title_fullStr | Tackling CMV in Transplant Recipients: Past, Present, and Future |
| title_full_unstemmed | Tackling CMV in Transplant Recipients: Past, Present, and Future |
| title_short | Tackling CMV in Transplant Recipients: Past, Present, and Future |
| title_sort | tackling cmv in transplant recipients past present and future |
| topic | Cytomegalovirus Interferon-gamma release assay Letermovir Maribavir Ganciclovir Bone marrow transplant |
| url | https://doi.org/10.1007/s40121-025-01159-6 |
| work_keys_str_mv | AT talschlaefferyosef tacklingcmvintransplantrecipientspastpresentandfuture AT liornesher tacklingcmvintransplantrecipientspastpresentandfuture |